HOUSTON and LONDON, May 29, 2025 ( GLOBE NEWSWIRE ) -- Baker Hughes ( NASDAQ: BKR ) , an energy technology company, announced Wednesday an award from Frontier Infrastructure Holdings ( "Frontier" ) , a Tailwater Capital LLC portfolio company, for 16 NovaLT™ gas turbines to power its data center ...

NORWALK, Conn., May 29, 2025 ( GLOBE NEWSWIRE ) -- FactSet ( NYSE: FDS | NASDAQ: FDS ) , a global financial digital platform and enterprise solutions provider, today announced it will release its financial and operating results for the third quarter fiscal 2025, ending May 31, 2025, on Monday, ...

Middleton, Massachusetts, May 29, 2025 ( GLOBE NEWSWIRE ) -- The QKS Group SPARK Matrix™ provides a competitive analysis and ranking of the leading Integrated Payment Platform vendors. Finastra has received strong ratings for its Integrated Payment Platform.

NEW YORK and WALTHAM, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company's ...

WATERTOWN, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. KYMR, a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the ...

RateHawk platform integration with Travelport+ will bring travel experts more choice in airline routes and unique ancillary services with multi-source carrier content

NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced that it will participate in three upcoming investor conferences in June: ...

NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- Syndax Pharmaceuticals ( Nasdaq: SNDX ) , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, ...

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ...

WALTHAM, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Zenas BioPharma, Inc. ( "Zenas" or the "Company" ) ( Nasdaq: ZBIO ) , a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced ...